Stockscreener 앱 받기
1.98
5.88%
0.11
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
Insider Spends US$82k Buying More Shares In Acrivon Therapeutics - simplywall.st
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares - Yahoo Finance
Price Action: Can Acrivon Therapeutics Inc ride the EV waveDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Acrivon Therapeutics CEO Blume-Jensen buys $82k in shares By Investing.com - Investing.com Nigeria
Top Brass Doubles Down on Acrivon With Bold Insider Buying Spree - TipRanks
Acrivon Therapeutics CEO Blume-Jensen buys $82k in shares - Investing.com
Volume Report: Is BMLPRJs ROE strong enoughEarnings Risk Report & Risk Managed Investment Signals - baoquankhu1.vn
Aug Decliners: Can Acrivon Therapeutics Inc ride the EV waveCEO Change & Smart Allocation Stock Tips - baoquankhu1.vn
Top Acrivon Executive Makes Bold Insider Move That Signals Growing Confidence - TipRanks
Insider Buying: Eric Devroe Acquires 10,000 Shares of Acrivon Th - GuruFocus
Acrivon Therapeutics COO Devroe buys $17k in shares By Investing.com - Investing.com UK
Acrivon Therapeutics COO Devroe buys $17k in shares - Investing.com
Acrivon Therapeutics (NASDAQ:ACRV) COO Purchases $17,200.00 in Stock - MarketBeat
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction - Intellectia AI
Movement Recap: What risks investors should watch in Acrivon Therapeutics Inc stockMarket Performance Summary & Safe Entry Momentum Stock Tips - Bộ Nội Vụ
Growth Value: Can Acrivon Therapeutics Inc expand into new marketsJuly 2025 Momentum & Entry Point Confirmation Signals - baoquankhu1.vn
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Lowered by Wall Street Zen - MarketBeat
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data By Investing.com - Investing.com South Africa
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com Australia
Acrivon reports 52% response rate in serous endometrial cancer trial By Investing.com - Investing.com Nigeria
How Acrivon Therapeutics Inc. stock compares to market leadersM&A Rumor & Long-Term Safe Investment Plans - Улправда
What is the fair value of Acrivon Therapeutics Inc. stock nowJuly 2025 Sector Moves & Verified Chart Pattern Signals - Улправда
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm
Why Acrivon Therapeutics Inc. stock could rally in 2025Treasury Yields & Community Consensus Picks - Улправда
Treasury Yields: Can Acrivon Therapeutics Inc. stock resist market sell offsWeekly Trade Summary & High Accuracy Investment Entry Signals - Улправда
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Acrivon Therapeutics Inc. stock remains a top recommendationInflation Watch & Fast Moving Market Watchlists - Улправда
Why retail investors pile into Acrivon Therapeutics Inc. stockSwing Trade & Long-Term Growth Stock Strategies - Улправда
Small-Cap Acrivon Showcases Tumor Reduction and Clinical Advancement in Major Trials, Shares Decline - Bitget
Acrivon Therapeutics Inc.: Rise or Retreat? - StocksToTrade
Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data - Nasdaq
Aug Gainers: What is the fair value of Acrivon Therapeutics Inc. stock now2025 Key Lessons & High Accuracy Trade Signal Alerts - Улправда
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating - TipRanks
Exit Recap: Why retail investors pile into Acrivon Therapeutics Inc. stockOptions Play & Safe Entry Point Alerts - ulpravda.ru
Why Is Acrivon Therapeutics Stock Falling Today?Acrivon Therapeutics (NASDAQ:ACRV) - Benzinga
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
What momentum indicators show for Acrivon Therapeutics Inc. stockQuarterly Profit Review & Verified Short-Term Plans - ulpravda.ru
Acrivon Therapeutics announces progress across pipeline - TipRanks
Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings - Benzinga
Acrivon Therapeutics stock plunges after mixed cancer trial results By Investing.com - Investing.com South Africa
Acrivon Therapeutics stock plunges after mixed cancer trial results - Investing.com
Is Acrivon Therapeutics Inc. stock overvalued by current metrics2025 Retail Activity & AI Enhanced Trading Alerts - Улправда
Acrivon Showcases Promising Phase 2b Oncology Data Update - TipRanks
Acrivon Therapeutics Stock (ACRV) Opinions on Clinical Data Release - Quiver Quantitative
Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe - Nasdaq
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks
New cancer drugs show tumor shrinkage in early trials - Stock Titan
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b - GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ACRV Stock Price Today - Stock Titan
4.73%
0.92%
자본화:
|
볼륨(24시간):